Solid Biosciences to Participate at the Jefferies Global Healthcare Conference
Solid Biosciences (NASDAQ: SLDB), a life sciences company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, announced its participation in the upcoming Jefferies Global Healthcare Conference. President and CEO Bo Cumbo and Chief Medical Officer Gabriel Brooks will engage in a fireside chat on June 4, 2025, at 2:00 pm ET. The presentation will be accessible via live webcast on the company's website's Investor Events page, with a replay available for 30 days afterward. Institutional investors can arrange meetings with management through their Jefferies representatives.
Solid Biosciences (NASDAQ: SLDB), un'azienda nel settore delle scienze della vita specializzata nello sviluppo di terapie genetiche di precisione per malattie neuromuscolari e cardiache, ha annunciato la sua partecipazione alla prossima Jefferies Global Healthcare Conference. Il Presidente e CEO Bo Cumbo e il Chief Medical Officer Gabriel Brooks parteciperanno a una conversazione informale il 4 giugno 2025, alle 14:00 ET. La presentazione sarà disponibile in diretta streaming sulla pagina Eventi Investitori del sito web aziendale, con la possibilità di rivederla per 30 giorni dopo l'evento. Gli investitori istituzionali possono organizzare incontri con il management tramite i loro rappresentanti Jefferies.
Solid Biosciences (NASDAQ: SLDB), una compañía de ciencias de la vida enfocada en el desarrollo de medicamentos genéticos de precisión para enfermedades neuromusculares y cardíacas, anunció su participación en la próxima Jefferies Global Healthcare Conference. El presidente y CEO Bo Cumbo y el director médico Gabriel Brooks participarán en una charla informal el 4 de junio de 2025 a las 2:00 pm ET. La presentación será accesible mediante una transmisión en vivo en la página de Eventos para Inversores del sitio web de la empresa, con una repetición disponible durante 30 días después. Los inversores institucionales pueden coordinar reuniones con la dirección a través de sus representantes de Jefferies.
Solid Biosciences (NASDAQ: SLDB)는 신경근 및 심장 질환에 대한 정밀 유전자 치료제를 개발하는 생명과학 회사로, 다가오는 Jefferies Global Healthcare Conference에 참여한다고 발표했습니다. 대표 겸 CEO 보 컴보(Bo Cumbo)와 최고 의료 책임자 가브리엘 브룩스(Gabriel Brooks)가 2025년 6월 4일 오후 2시(동부시간)에 대담을 진행할 예정입니다. 발표는 회사 웹사이트의 투자자 이벤트 페이지에서 라이브 웹캐스트로 시청할 수 있으며, 이후 30일간 다시보기 기능도 제공됩니다. 기관 투자자는 제퍼리스 담당자를 통해 경영진과의 미팅을 조율할 수 있습니다.
Solid Biosciences (NASDAQ : SLDB), une entreprise en sciences de la vie spécialisée dans le développement de médicaments génétiques de précision pour les maladies neuromusculaires et cardiaques, a annoncé sa participation à la prochaine Jefferies Global Healthcare Conference. Le président-directeur général Bo Cumbo et le directeur médical Gabriel Brooks participeront à une discussion informelle le 4 juin 2025 à 14h00 ET. La présentation sera accessible en direct via un webinaire sur la page Événements Investisseurs du site web de l'entreprise, avec une rediffusion disponible pendant 30 jours après l'événement. Les investisseurs institutionnels peuvent organiser des rendez-vous avec la direction via leurs représentants Jefferies.
Solid Biosciences (NASDAQ: SLDB), ein Unternehmen im Bereich der Lebenswissenschaften, das sich auf die Entwicklung präziser genetischer Medikamente für neuromuskuläre und Herzkrankheiten spezialisiert hat, gab seine Teilnahme an der kommenden Jefferies Global Healthcare Conference bekannt. Präsident und CEO Bo Cumbo sowie Chief Medical Officer Gabriel Brooks werden am 4. Juni 2025 um 14:00 Uhr ET an einem Gespräch teilnehmen. Die Präsentation wird live über einen Webcast auf der Investor-Events-Seite der Unternehmenswebsite verfügbar sein, mit einer Wiedergabeoption für 30 Tage danach. Institutionelle Investoren können über ihre Jefferies-Vertreter Meetings mit dem Management arrangieren.
- None.
- None.
CHARLESTOWN, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, announced that Bo Cumbo, President and CEO, and Gabriel Brooks, M.D., Chief Medical Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, at 2:00 pm ET.
A live webcast of the fireside chat will be available on the Events page of the Investors section of the Company website or by clicking here. The webcast replay will be archived for 30 days on the Events page.
Institutional investors interested in meeting with management during the conference may reach out to their Jefferies representative.
About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases. For more information, please visit www.solidbio.com.
Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com
Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com
FAQ
When is Solid Biosciences (SLDB) presenting at the Jefferies Global Healthcare Conference 2025?
Who will represent Solid Biosciences (SLDB) at the Jefferies Healthcare Conference?
How can investors access Solid Biosciences' (SLDB) presentation at the Jefferies Conference?
What type of medicines does Solid Biosciences (SLDB) develop?
